Highbridge Capital Management LLC acquired a new position in Kenvue Inc. (NYSE:KVUE – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,174,353 shares of the company’s stock, valued at approximately $20,258,000. Highbridge Capital Management LLC owned approximately 0.06% of Kenvue at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in KVUE. Norges Bank bought a new position in Kenvue in the 4th quarter worth $756,862,000. Van ECK Associates Corp grew its position in shares of Kenvue by 101.3% in the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after buying an additional 9,240,434 shares during the period. American Century Companies Inc. grew its position in shares of Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after buying an additional 6,781,640 shares during the period. Bessemer Group Inc. grew its position in shares of Kenvue by 156.2% in the 4th quarter. Bessemer Group Inc. now owns 8,491,343 shares of the company’s stock worth $146,475,000 after buying an additional 5,177,404 shares during the period. Finally, Mondrian Investment Partners LTD purchased a new stake in shares of Kenvue in the 3rd quarter worth about $79,269,000. 97.64% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.59% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Kenvue
Kenvue Stock Performance
Shares of KVUE stock opened at $17.72 on Friday. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The company’s 50-day moving average is $17.37 and its 200 day moving average is $17.48. The company has a market capitalization of $34.01 billion, a price-to-earnings ratio of 20.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the prior year, the firm posted $0.24 EPS. Kenvue’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts expect that Kenvue Inc. will post 1.16 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Stories
- Five stocks we like better than Kenvue
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
